Oncothyreon plans public offers of convertible preferred, common shares

By Devika Patel

Knoxville, Tenn., Sept. 17 – Oncothyreon Inc. will conduct a public offering of series A convertible preferred stock as well as a concurrent offering of common stock with a 30-day greenshoe option, according to separate 424B5 filings with the Securities and Exchange Commission.

Cowen and Co., LLC is the sole book-running manager for both deals.

Proceeds of both offerings will be used for development of ONT-380 and ONT-10 and general corporate purposes.

Oncothyreon is a Seattle biotechnology company. It makes the Stimuvax cancer vaccine that is being evaluated in two Phase 3 clinical trials for the treatment of non-small cell lung cancer.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.